ArticleInvestigative and clinical urology2020
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
Sung Han Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.